Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Central neurocytomas

S E Schild1, B W Scheithauer, M G Haddock

  • 1Mayo Clinic Scottsdale, Department of Radiation Oncology, Arizona 85259, USA.

Cancer
|February 15, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expression of leukemia inhibitory factor in craniopharyngioma.

Endocrine pathology·2016
Same author

Localization of vascular endothelial growth factor in nontumorous human pituitaries.

Endocrine pathology·2016
Same author

Invasive thymoma metastatic to the cavernous sinus.

Surgical neurology international·2013
Same author

Tumefactive demyelination and glioblastoma: a rare collision lesion.

Clinical neuropathology·2011
Same author

Dysembryoplastic neuroepithelial tumor and calcifying pseudoneoplasms of the neuraxis: a collision of two seizure-associated lesions.

Clinical neuropathology·2011
Same author

Transformation of low grade glioma and correlation with outcome: an NCCTG database analysis.

Journal of neuro-oncology·2010
Same journal

Toward exercise as standard care for older cancer survivors.

Cancer·2026
Same journal

Maintenance therapy in gynecologic malignancies: Current and future state.

Cancer·2026
Same journal

Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

Cancer·2026
Same journal

Large-scale osteosarcoma sequencing reveals age-associated genomic architectures.

Cancer·2026
Same journal

EZH2 inhibitor tazemetostat voluntarily withdrawn from market.

Cancer·2026
Same journal

Nivolumab and chemotherapy combination approved for previously untreated Hodgkin lymphoma.

Cancer·2026
See all related articles

Gross total resection (GTR) offers high survival and local control for central neurocytomas. Radiotherapy (RT) after subtotal resection (STR) significantly improves local control in these rare brain tumors.

Area of Science:

  • Neuro-oncology
  • Neurosurgery
  • Radiation Oncology

Background:

  • Central neurocytomas are rare tumors requiring evaluation of treatment outcomes.
  • Histologically confirmed central neurocytomas necessitate analysis of patient prognoses.

Purpose of the Study:

  • To examine the treatment outcomes for patients diagnosed with central neurocytomas.
  • To assess the impact of surgical resection extent and radiotherapy on patient survival and local control.

Main Methods:

  • Retrospective analysis of 32 patients with central neurocytomas.
  • Evaluation of treatment modalities including surgery, chemotherapy, and radiotherapy (RT).
  • Follow-up duration ranged from 2.3 to 15.3 years.

Main Results:

Related Experiment Videos

  • Overall 5-year survival and local control rates were 81% and 79%, respectively.
  • Gross total resection (GTR) showed higher local control (100%) and survival (90%) rates compared to subtotal resection (STR) (70% and 77%).
  • Postoperative radiotherapy (RT) significantly improved 5-year local control in STR patients (100% with RT vs. 50% without RT, P=0.02).

Conclusions:

  • GTR is associated with excellent local control and survival for central neurocytomas.
  • Postoperative RT significantly enhances local control for patients undergoing STR.
  • Central neurocytomas have a favorable prognosis, with an 81% 5-year survival rate.